logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10456408 B1

PDFFull Text
Date of Patent:
Oct. 29, 2019

Filed:

Jul. 20, 2018

Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Applicant:

Essentialis, Inc., Redwood City, CA (US);

Inventor:

Neil M. Cowen, Carlsbad, CA (US);

Assignee:

ESSENTIALIS, INC., Redwood City, CA (US);

Attorney:

Cooley LLP

Primary Examiner:

Taylor V Oh

Int. Cl.
CPC ...
A61K 31/549 (2006.01); C07D 285/18 (2006.01); C07D 285/22 (2006.01); A61K 38/27 (2006.01); A61K 45/06 (2006.01); A61K 31/137 (2006.01); A61K 31/155 (2006.01); A61K 31/551 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/50 (2006.01);
U.S. Cl.
CPC ...
A61K 31/549 (2013.01); A61K 9/00 (2013.01); A61K 9/0004 (2013.01); A61K 9/2054 (2013.01); A61K 9/5026 (2013.01); A61K 9/5042 (2013.01); A61K 9/5047 (2013.01); A61K 31/137 (2013.01); A61K 31/155 (2013.01); A61K 31/551 (2013.01); A61K 38/27 (2013.01); A61K 45/06 (2013.01); C07D 285/18 (2013.01); C07D 285/22 (2013.01); A61K 2300/00 (2013.01);
Abstract

Provided are immediate or prolonged administration of certain potassium ATP (K) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving Kchannels. Also provided are pharmaceutical formulations, methods of administration and dosing of Kchannel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering Kchannel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.

Find Patent Forward Citations

Loading…